Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA. Novel influenza virus strains caused by genetic drift and viral recombination emerge periodically to which humans have little or no immunity, resulting in devastating pandemics. Influenza A can exist in a variety of animals; however it is in birds that all subtypes can be found. These subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. During 1997, an H5N1 avian influenza virus was determined to be the cause of death in 6 of 18 infected patients in Hong Kong. The more recent virulent strain of H5N1 is now seen in Africa and Europe, as well as in southeast Asia. There is some evidence of human to human spread of this virus, but it is thought that the transmission efficiency was fairly low. HA interacts with cell surface proteins containing oligosaccharides with terminal sialyl residues. Virus isolated from a human infected with the H5N1 strain in 1997 could bind to oligosaccharides from human as well as avian sources, indicating its species-jumping ability. While efforts were made to use relatively conserved regions of the viral sequence as the antigen, the influenza virus genome has drifted somewhat from what was first reported. However, this antibody was able to recognize peptides derrived from viruses from Indonesian human patients infected in 2007.

Abbiotec坚信与我们的科学家，客户，合作者和分销商社区建立牢固而有意义的合作伙伴关系。我们通过研究合作与社区分享我们的想法，并通过有益于生命科学界的创新和有用的产品来回馈青睐。我们欢迎有关研究或产品创意的讨论，我们将努力为此类讨论提供最有利和最机密的环境。Abbiotec利用专有技术和特殊资源开发自己的产品，以实现高质量的生产和控制。我们还从其他合作伙伴（例如个人科学家，大学外发许可部门和其他生物技术公司）获得产品和想法的许可。被许可的技术或想法被开发为商业产品，并通过我们的营销和销售网络在全球范围内销售。